Supplementary Figure S1. Neoadjuvant immunotherapy is more effective at reducing metastatic burden. Supplementary Figure S2. Late neoadjuvant Treg depletion is more effective than adjuvant Treg depletion in eradicating metastatic disease. Supplementary Figure S3. Efficacy of neoadjuvant immunotherapy is dependent on surgical resection of the primary tumor. Supplementary Fig. S4. Neoadjuvant compared to adjuvant chemotherapy does not lead to improved survival benefit. Supplementary Figure S5. Long-term survivors following neoadjuvant immunotherapy treatment are tumor free and display immunological memory. Supplementary Figure S6. Efficacy of neoadjuvant Treg depletion depends on T and NK cells. Supplementary Figure S7. Kinetics of gp70 tumor-specific CD8+ T cells in peripheral blood following neoadjuvant or adjuvant Treg depletion. Supplementary Figure S8. Neoadjuvant immunotherapy increases tumor-specific CD8+ T cells in the peripheral organs and primary tumor. Supplementary Figure S9. Neoadjuvant compared to adjuvant immunotherapy increases the number of tumor-specific CD8+ T cells with effector phenotype.